Welcome to Carver's European Union Regulatory Updates for April 05, 2026.

The European Central Bank, or ECB, has announced a significant change in how it supervises banks' internal credit risk models. Moving away from the previous ex ante assessment approach, the ECB will now allow banks to implement material changes to their internal models shortly after submitting a complete application. This shift to ex post assessment is contingent on banks’ internal control functions confirming compliance with regulatory requirements before implementation. The European Banking Authority, or EBA, has also revised the materiality criteria for model changes, reducing the number of changes that require ECB approval. This streamlined process focuses supervisory resources on higher-risk cases, with targeted on-site investigations reserved only for those. Regulatory capital benefits from model changes that lower risk weights will be subject to a capital floor until the ECB completes its on-site investigation. This update aims to reduce supervisory workload and delays, enabling banks to be more agile in managing credit risk models while maintaining high supervisory standards and resilience.

In Germany, the Paul-Ehrlich-Institut has authorized Bavarian Nordic to place French-labelled Vimkunya vaccine packs on the German market from April 2 to April 8, 2026. This temporary authorization, granted under specific sections of the Medicinal Products Act, allows the use of French-labelled vaccine packaging accompanied by a German package leaflet taped to the packaging. Users are instructed to follow the package leaflet for vaccine administration.

Also in Germany, Sengewald Klinikprodukte GmbH has issued an urgent field safety notice concerning two lots of SECUDRAPE OP-Mantel surgical gowns. These gowns, previously labeled as high performance, showed nonconforming results in microbial penetration tests and have been downgraded to standard performance gowns. Distributors are required to inform customers accordingly. The affected gowns should only be used for procedures appropriate for standard performance gowns.

Turning to pharmacovigilance in the European Union, the Pharmacovigilance Risk Assessment Committee, or PRAC, issued a warning in March 2026 regarding the vaccine Ixchiq. The product information for Ixchiq will be updated to reflect that serious side effects, including aseptic meningitis, have been observed in healthy young adults. Healthcare providers are advised to monitor for symptoms such as confusion, drowsiness, fever, headache, seizures, and neck stiffness following vaccination. Immediate medical attention is recommended if these symptoms occur.

In the European Union’s medical device sector, a notified body identified as 2797 has released an expert decision and opinion dated July 15, 2025, concerning implantable cardiac devices. The update focuses on the clinical evaluation of the INGEVITY+ lead device extension used for left bundle branch pacing. The expert panel recommends that notified bodies incorporate these opinions into conformity assessment reports. Manufacturers are advised to implement expanded post-market clinical follow-up, or PMCF, plans to monitor safety and clinical outcomes across multiple centers and physicians. Detailed clinical event data should be collected post-implantation and during follow-up.

That wraps up today's regulatory updates. Visit carveragents.ai for more information.